Esreboxetine

埃巴西汀

Report date: 2026/02/10 20:00:22
NME

Base Information

Drug NameEsreboxetine
Drug Alias Nameesreboxetina恶泼西汀艾司瑞波西汀esreboxetinum[S,S]-Reboxetine +[7] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNorepinephrine reuptake inhibitors
TargetsNorepinephrine transporter
Therapy Area/IndicationsAttention Deficit Disorder with HyperactivityDepressive Disorder, MajorPain +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[29] 
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesPfizer IncAxsome Therapeutics Inc
Inactive CompaniesViatris
Active IndicationsFibromyalgia
Inactive IndicationsAttention Deficit Disorder with HyperactivityDepressive Disorder, MajorPain +[5] 

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG